Evidence map›Paper›PMID 30165574›Full record

ReviewCardiovascular research2018

From design to the clinic: practical guidelines for translating cardiovascular nanomedicine.

Iwona Cicha, Cédric Chauvierre, Isabelle Texier, Claudia Cabella, Josbert M Metselaar, János Szebeni, László Dézsi, Christoph Alexiou, François Rouzet, Gert Storm and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiovascular research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. The Interplay Among Biomolecules and Nanomaterials.International journal of molecular sciences · 2025
    Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions.Small (Weinheim an der Bergstrasse, Germany) · 2024
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Iwona CichaCardiovascular Nanomedicine Unit, Section of Experimental Oncology und Nanomedicine (SEON), ENT-Department, University Hospital Erlangen, Glückstr. 10a, Erlangen, Germany.
Cédric ChauvierreINSERM U1148, LVTS, Paris Diderot University, Paris 13 University, X. Bichat Hospital, 46 rue H. Huchard, Paris, France.
Isabelle TexierUniversity Grenoble Alpes CEA, LETI, DTBS, Grenoble, France.
Claudia CabellaCentro Ricerche Bracco, Bracco Imaging Spa, Colleretto Giacosa, Italy.
Josbert M MetselaarDepartment of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany.
János SzebeniNanomedicine Research and Education Center, Department of Pathophysiology, Semmelweis University, Budapest, Hungary.
László DézsiNanomedicine Research and Education Center, Department of Pathophysiology, Semmelweis University, Budapest, Hungary.
Christoph AlexiouCardiovascular Nanomedicine Unit, Section of Experimental Oncology und Nanomedicine (SEON), ENT-Department, University Hospital Erlangen, Glückstr. 10a, Erlangen, Germany.
François RouzetINSERM U1148, LVTS, Paris Diderot University, Paris 13 University, X. Bichat Hospital, 46 rue H. Huchard, Paris, France.
Gert StormDepartment of Pharmaceutics, University of Utrecht, Utrecht, The Netherlands.
Erik StroesDepartment of Vascular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands.
Donald BruceEdinethics Ltd, Edinburgh, UK.
Neil MacRitchieInstitute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Pasquale MaffiaInstitute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Didier LetourneurINSERM U1148, LVTS, Paris Diderot University, Paris 13 University, X. Bichat Hospital, 46 rue H. Huchard, Paris, France.

Funding

British Heart Foundation RE/13/5/30177
6 · The paper itself

Abstract

Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicomponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications.

Indexed as

AnimalsCardiologyCardiovascular DiseasesDisease Models, AnimalHumansNanomedicinePatient SafetyPractice Guidelines as TopicRisk AssessmentToxicity TestsTranslational Research, Biomedical

Identifiers

PMID30165574
PMCPMC6198738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.